Corey-Bloom Jody, Gluhm Shea, Herndon Andrew, Haque Ameera S, Park Sungmee, Gilbert Paul E
Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.
San Diego State University-University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA.
J Huntingtons Dis. 2016;5(1):91-6. doi: 10.3233/JHD-150175.
Visuospatial deficits have been described in Huntington's disease (HD); however, the extent of these deficits remains unclear. The Benton Judgment of Line Orientation (JoLO) Test, commonly used to assess visuospatial ability, requires minimal motor involvement. It has demonstrated sensitivity to visuospatial deficits in Parkinson's disease; however, few studies have examined performance on this test in HD.
The objective of the current study was to assess visuospatial ability in premanifest and manifest HD using the JoLO.
A global cognitive measure, the Mattis Dementia Rating Scale (DRS), was used to stratify manifest HD patients as mild (DRS ≥129) vs. moderate-severe (DRS ≤128). Fifty mild, 42 moderate-severe, and 30 premanifest HD subjects, as well as 35 matched controls, were administered the JoLO. HD Burden of Pathology (BOP) scores were used as a measure of disease severity.
Results revealed that the total manifest HD sample (p < 0.001), in addition to the mild (p = 0.028), and moderate-severe (p < 0.001), but not premanifest, HD subjects scored significantly lower on the JoLO compared to normal controls.
Our results suggest that the JoLO is useful for detecting visuospatial deficits across various stages of manifest HD. However, any visuospatial impairment that might be present during the premanifest stage of HD was not detected using the JoLO in the present sample.
亨廷顿舞蹈病(HD)患者存在视觉空间缺陷,但其缺陷程度尚不清楚。常用于评估视觉空间能力的本顿直线方向判断(JoLO)测试所需的运动参与最少。该测试已被证明对帕金森病的视觉空间缺陷具有敏感性;然而,很少有研究考察HD患者在此测试中的表现。
本研究旨在使用JoLO测试评估临床前期和临床期HD患者的视觉空间能力。
使用整体认知测量工具马蒂斯痴呆评定量表(DRS)将临床期HD患者分为轻度(DRS≥129)和中重度(DRS≤128)。对50名轻度、42名中重度和30名临床前期HD受试者以及35名匹配的对照者进行JoLO测试。HD病理负担(BOP)评分用作疾病严重程度的指标。
结果显示,整个临床期HD样本(p<0.001),以及轻度(p=0.028)和中重度(p<0.001)HD受试者在JoLO测试中的得分显著低于正常对照组,但临床前期HD受试者未出现此情况。
我们的结果表明,JoLO测试有助于检测临床期HD各阶段的视觉空间缺陷。然而,在本样本中使用JoLO测试未检测到HD临床前期可能存在的任何视觉空间损害。